Axsome Therapeutics Inc
AXSM
Market Cap$3.67B
Close$
$62.73
18% downside
Current Fair Value
18% downsideOvervalued by 18% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.67 Billion |
|---|---|
| Enterprise Value | $3.53 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-6.39 |
| Beta | 0.87 |
| Outstanding Shares | 47,495,827 |
| Avg 30 Day Volume | 599,809 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -12.4 |
|---|---|
| PEG | -2.43 |
| Price to Sales | 15.31 |
| Price to Book Ratio | 25.51 |
| Enterprise Value to Revenue | 14.07 |
| Enterprise Value to EBIT | -14.41 |
| Enterprise Value to Net Income | -12 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 1.31 |
Revenue Sources
No data
ESG Score
No data
About Axsome Therapeutics Inc
CEO: Herriot Tabuteau Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. For the many people facing unsatisfactory tre...